Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

Organigram Global Inc. (OGI) vs Organogenesis (ORGO)

Organigram Global Inc. and Organogenesis are both Drug Manufacturers Specialty & Generic companies. Organogenesis is the larger, with a market value of $207.1M against $155.1M — 1.3× the size. Organogenesis has negative trailing earnings, so its P/E is not meaningful; Organigram Global Inc. trades at 2.4×. Organigram Global Inc. grew revenue faster over the last twelve months: 39.5% against 6.50%. Organigram Global Inc. has the higher net margin (28.4% vs −22.2%) and the higher return on invested capital (−1.53% vs −20.0%). Across the 19 metrics below, Organigram Global Inc. leads on 11 and Organogenesis on 8.

Valuation

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
P/E 2.37 n/m 20.14
P/S 0.67 0.39 2.25
P/B 0.42 1.22 1.90
Price to free cash flow n/m 8.64 16.54
EV/EBITDA 16.79 n/m 12.29
EV/Sales 0.70 0.33 2.56
Earnings yield 42.26% (60.71%) (2.99%)
Free cash flow yield (14.22%) 11.57% 0.00%

Profitability

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
Gross margin 36.47% 70.35% 53.94%
Operating margin (3.91%) (7.84%) 0.00%
Net margin 28.44% (22.23%) 0.00%
Free cash flow margin (9.46%) 4.56% 0.00%
Return on equity 20.20% (53.31%) (0.40%)
Return on assets 12.70% (23.44%) (3.32%)
Return on invested capital (1.53%) (19.97%) 0.00%

Growth

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
Revenue growth (TTM) 39.51% 6.50% 10.01%
EPS growth (last fiscal year) 60.00% 1,600.00% —
Revenue growth, 5-year CAGR 24.30% 10.77% 6.74%
Net income growth, 5-year CAGR 0.00% 3.04% 0.00%

Health

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
Debt to equity 0.04 0.07 0.05
Current ratio 2.61 3.52 2.31
Net debt to EBITDA (31.56) (1.14) 0.85

Dividend

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
Dividend yield — — 1.70%
Payout ratio 0.00 0.00 0.00

Size

Metric OGI ORGO Drug Manufacturers Specialty & Generic median
Market cap 155.11m 207.13m 337.35m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack